STOCK TITAN

Eyenovia Announces Pricing of $5M Registered Direct Offering

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Eyenovia announced the pricing of a $5 million registered direct offering, involving the sale of 7,575,757 shares of common stock and accompanying warrants. Each share and warrant combination is priced at $0.66, with warrants exercisable at $0.69 per share starting six months from issuance and expiring in 5.5 years. The offering is expected to close around July 1, 2024, subject to customary conditions. Gross proceeds are anticipated to be $5 million before fees and expenses. The funds will support the commercialization of Mydcombi and clobetasol propionate, the CHAPERONE pediatric myopia study, and general corporate purposes, including debt repayment. Chardan is leading the placement, with Brookline Capital Markets acting as co-placement agent.

Positive
  • Anticipated gross proceeds of $5 million from the offering.
  • Funds to be used for Mydcombi and clobetasol propionate commercialization.
  • Completion of CHAPERONE pediatric myopia study supported by the offering.
Negative
  • Potential shareholder dilution due to the issuance of 7,575,757 new shares.
  • Additional dilution risk from 7,575,757 new warrants exercisable at $0.69.

Eyenovia's direct offering of $5 million presents several key insights. Direct offerings help companies raise capital without underwriting fees, which is cost-effective. However, the offering price of $0.66 per share is quite low, potentially indicating the company’s need for immediate cash infusion. This can be seen as a negative signal about their current financial health.

Warrants provide additional upside to investors but at a lower exercise price of $0.69, slightly higher than the offering price, which means the company expects its stock price may not see significant short-term appreciation. It also suggests the company is providing a sweetener to attract investment, which could dilute existing shares if the warrants are exercised.

In the short term, this financing will provide necessary funds for their product launches and ongoing research, which is positive. However, in the long term, if the stock price doesn’t improve, existing shareholders might face significant dilution, impacting their returns.

The allocation of funds towards commercialization activities and the completion of the CHAPERONE pediatric myopia clinical study points to a strategic focus on expanding Eyenovia's market presence and product pipeline. This is a positive sign as it shows proactive steps towards growth and revenue generation. However, the market's reception of Mydcombi and clobetasol propionate will be critical. If these products fail to gain traction, the investment might not yield the expected returns.

Furthermore, the emphasis on working capital and potential debt repayment indicates that Eyenovia is also focusing on maintaining operational stability. This balanced approach can be reassuring for investors, but it also highlights the company’s financial constraints.

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current largest stockholder, providing for the purchase and sale of 7,575,757 shares of common stock, and warrants to purchase up to 7,575,757 shares of common stock (the "Offering"). The combined offering price for each share of common stock and accompanying warrant is $0.66.

The warrants will have an exercise price of $0.69 per share, are exercisable six months from issuance, and will expire 5.5 years from the date of issuance. The closing of the Offering is expected to occur on or about July 1, 2024, subject to the satisfaction of customary closing conditions. All of the securities in the Offering are being sold by Eyenovia.

Chardan is acting as the lead-placement agent for the Offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is also acting as a co-placement agent for the Offering.

The gross proceeds to Eyenovia from this Offering are expected to be approximately $5 million, before deducting the placement agents’ fees and other offering expenses payable by Eyenovia. Eyenovia intends to use the net proceeds from this Offering to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study, and for working capital and general corporate purposes, which may include the repayment of a portion of existing indebtedness.

The securities described above are being offered by Eyenovia pursuant to its previously filed shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission (the “SEC”) on December 23, 2021. The Offering may be made only by means of a prospectus supplement and accompanying prospectus. A prospectus supplement relating to the Offering will be filed with the SEC and once filed, will be available on the SEC’s website at www.sec.gov. When available, copies of the prospectus supplement and the accompanying base prospectus relating to the Offering may also be obtained by contacting Chardan Capital Markets, LLC, Attn: Capital Markets, One Pennsylvania Plaza, Suite 4800, New York, New York 10119, by email at prospectus@chardan.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Eyenovia, Inc.

Eyenovia, Inc. is an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis, Clobetasol Propionate Ophthalmic Suspension, 0.05% for postsurgical inflammation and pain, and developing the Optejet® device for use both in connection with its own drug-device therapeutic product for pediatric progressive myopia as well as out-licensing for additional indications. For more information, please visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Forward Looking Statements

Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology, the timing for sales growth of our approved products, and the outcome of the process to explore strategic alternatives to maximize shareholder value. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, those relating to the Offering, the closing of the Offering, the amount and anticipated use of proceeds from the Offering, the costs, design, initiation and enrollment, timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our products and product candidates; the potential advantages of our products, product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our products and product candidates; our estimates regarding the potential market opportunity for our products and product candidates; reliance on third parties to develop and commercialize our products and product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products and product candidates; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; and our competitive position.

Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com


FAQ

What is the purpose of Eyenovia's $5M registered direct offering?

The funds will support the commercialization of Mydcombi and clobetasol propionate, the completion of the CHAPERONE pediatric myopia study, and general corporate purposes including debt repayment.

How many shares and warrants are being issued in Eyenovia's offering?

Eyenovia is issuing 7,575,757 shares of common stock and warrants to purchase up to 7,575,757 shares.

At what price are Eyenovia's shares and warrants being offered?

The combined offering price for each share of common stock and accompanying warrant is $0.66, with the warrant exercise price set at $0.69 per share.

When is the closing date for Eyenovia's registered direct offering?

The closing of the offering is expected to occur on or about July 1, 2024, subject to customary closing conditions.

Who is acting as the placement agent for Eyenovia's registered direct offering?

Chardan is acting as the lead-placement agent, with Brookline Capital Markets as the co-placement agent.

Eyenovia, Inc.

NASDAQ:EYEN

EYEN Rankings

EYEN Latest News

EYEN Stock Data

65.75M
61.45M
16.18%
14.76%
7.28%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
NEW YORK